Table 4. Summary of studies addressing the outcome of penile girth enhancement using HA fillers.
| Trade name (manufacturer, country) |
Study design | Sample size | Mean penile girth increase at 24 weeks, mm | Complications | Injection dosage, mL (mean±SD) | HA concentration, mg/mL | Particle size, µm | Cross-linking, degree |
|---|---|---|---|---|---|---|---|---|
| Potenfill (Medytox, Korea) [14] |
Prospective, patient/evaluator-blinded, randomized, multicenter trial | 65 (HA: 33, PLA: 32) | 21 | Injection site deformation: 1; injection site inflammation: 1 | 20.8±1.5 | 20 | ~700 | BDDE, 10% |
| HyaFilia Impact (CHA Meditech, Korea) [15] | Prospective, patient/ evaluator-blinded, randomized, multicenter trial | 62 (HA: 30, PLA: 32) |
19.1 | Injection site inflammation: 1; injection site pain: 2 | 16.4±2.7 | 20 | ~500 | BDDE, 6% |
| THE CHAEUM; Shape 10 (Hugel Bio, Korea) [13] |
Prospective, patient/ evaluator-blinded, randomized, multicenter trial | 59 (HA: 30, PLA: 29) |
20.6 | Injection site induration: 1 | 19.1±1.4 | 20 | ~600 | BDDE, no record |
| Doublofill (Humedix, Korea)a |
Prospective, patient/ evaluator-blinded, randomized, multicenter trial | 64 (HA: 32, PLA: 32) |
22.7 | Injection site inflammation: 2 | 19.7±0.7 | 23 | ~700 | BDDE, 12% |
HA: hyaluronic acid, PLA: polylactic acid, BDDE: 1,4-butanediol diglycidyl ether.
aCurrent study.